Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects

• Published in: Journal of cardiovascular pharmacology Vol. 49; no. 3; p. 167
• Main Authors: Jakubowski, Joseph A, Payne, Christopher D, Weerakkody, Govinda J, Brandt, John T, Farid, Nagy A, Li, Ying G, Naganuma, Hideo, Lachno, D Richard, Winters, Kenneth J
• Format: Journal Article
• Language: English
• Published: United States 01.03.2007
• Subjects: Adenosine Diphosphate; Adolescent; Adult; Aspirin - adverse effects; Aspirin - pharmacology; Bleeding Time; Collagen; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Peptide Fragments; Piperazines - administration & dosage; Piperazines - adverse effects; Piperazines - pharmacology; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - pharmacology; Prasugrel Hydrochloride; Thiophenes - administration & dosage; Thiophenes - adverse effects; Thiophenes - pharmacology; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacology

The aims of this open-label, randomized, dose-escalation pharmacodynamic study of prasugrel, an orally active antiplatelet agent, were to assess its interaction with aspirin (ASA, 325 mg) in healthy subjects after a loading dose (LD) and subsequent 5 days of once-daily maintenance doses (MD) of pras...